an extension of indication for oseltamivir (Tamiflu®) to include treatment of children less than 6 months

<p align="justify">The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has approved an extension of indication for oseltamivir (Tamiflu®) to include treatment of children less than 6 months of age during pandemic influenza and post-exposure prophylaxis for children less than 1 year of age. In parallel the Committee has approved instructions to prepare home and pharmacy extemporaneous formulations from Tamiflu 30, 45 and 75mg capsules and dosing recommendations from these extemporaneous formulations for children under 1 year of age. Additional information including the recommended updated product information will be published shortly.</p>